Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-03-24
2008-07-29
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016700, C514S475000, C514S478000, C514S588000
Reexamination Certificate
active
07405194
ABSTRACT:
The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
REFERENCES:
patent: 4703107 (1987-10-01), Monsigny et al.
patent: 5180735 (1993-01-01), Kishimoto et al.
patent: 5180738 (1993-01-01), Kishimoto et al.
patent: 5290807 (1994-03-01), Folkman et al.
patent: 5422363 (1995-06-01), Yanai et al.
patent: 5648382 (1997-07-01), Billington et al.
patent: 5698586 (1997-12-01), Kishimoto et al.
patent: 5767293 (1998-06-01), Oku et al.
patent: 5789405 (1998-08-01), Oku et al.
patent: 5846562 (1998-12-01), Yanai et al.
patent: 6017954 (2000-01-01), Folkman et al.
patent: 6086865 (2000-07-01), Folkman et al.
patent: 6548477 (2003-04-01), Olson et al.
patent: 6584477 (2003-06-01), Mosher, Jr.
patent: 6919307 (2005-07-01), Olson et al.
patent: 7037890 (2006-05-01), Olson et al.
patent: 7084108 (2006-08-01), Olson et al.
patent: 2002/0151493 (2002-10-01), Olson et al.
patent: 2005/0059585 (2005-03-01), Olson et al.
patent: 2005/0130903 (2005-06-01), Olson et al.
patent: 2006/0069028 (2006-03-01), Olson et al.
patent: 0354767 (1990-02-01), None
patent: 0357061 (1990-03-01), None
patent: 0359036 (1990-03-01), None
patent: 0387650 (1990-09-01), None
patent: 0415294 (1991-03-01), None
patent: 0658342 (1995-06-01), None
patent: WO-98/13059 (1998-04-01), None
patent: WO-98/56372 (1998-12-01), None
patent: WO-99/59986 (1999-11-01), None
patent: WO-99/61432 (1999-12-01), None
patent: WO-00/64486 (2000-11-01), None
patent: WO-00/69472 (2000-11-01), None
Denmeade SR, et al. “Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.”Cancer Res. Jun. 15, 1998;58(12):2537-40.
Griffith EC, et al. “Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2,”Proc. Natl. Acad. Sci. USA, vol. 95:15183-15188 (1998).
Griffith EC, et al. “Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin”.Chem Biol. Jun. 1997;4(6):461-71.
Han CK, et al. “Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2.”Bioorg Med Chem Lett. Jan. 3, 2000;10(1):39-43.
Landquist, JK “Some Degradation Products of Fumagillin”J. Chem. Soc. 1956: 4237-4245.
Tarbell et al. “Chemical Evidence For At Least Two Different Precursors To Cyclohexene Formed By Electron Irradiation Of Cyclohexane,”Journal of the American Chemical Society, Feb. 20, 1960; 82:1005-1007.
Liu S, et al. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science. Nov. 13, 1998;282(5392):1324-7.
Sin N, et al. “The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2.”Proc Natl Acad Sci U S A. Jun. 10, 1997;94(12):6099-103.
Timar F, et al. “The antiproliferative action of a melphalan hexapeptide with collagenase-cleavable site.”Cancer Chemother Pharmacol. 1998;41(4):292-8.
Turk BE, et al. “Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells.”Chem Biol. Nov. 1999;6(11):823-33.
De Marre, A. et al. “Synthesis and evaluation of macromolecular prodrugs of mitomycin C,”Journal of Controlled Release36(1/2):87-97 (1995).
Nichifor, M. et al. “Chemical and enzymatic hyrdolysis of dipeptide derivatives of 5-fluorouracil,”Journal of Controlled Release47:271-281 (1997).
Zhang, Peng, et al., “Angiogenesis Inhibitors Specific for Methionine Aminopeptidase 2 as Drugs for Malaria and Leishmaniasis,”Journal of Biomedical Science, vol. 9:34-40 (2002).
Arico-Muendel Christopher C.
Birktoft Jens
Cook Charles M.
Lee Lily
Morgan Barry
Praecis Pharmaceuticals Inc.
Russel Jeffrey E
Sieburth Kathryn L.
Venetianer Stephen
LandOfFree
Therapeutic agents and methods of use thereof for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agents and methods of use thereof for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents and methods of use thereof for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3969825